Table 3—

Drugs evaluated in relapsed small cell lung cancer(phase II trials)

	Patients n	OR %	OS	Conclusion	[Ref.]
Gemcitabine	27	0	6 months	Limited activity	76
	41	13	17 weeks	Modest activity	77
	46	12	7 months	Modest activity	78
Irinotecan	16	47	7 months	Active agent	79
Paclitaxel	24	29	100 days	Active agent	41
	44	20	4 months	Active agent	80
Vinorelbine	24	13		Modest activity	81
	26	16		Modest activity	82
Pemetrexed	43	S: n = 1 PR; Rs: n = 1 PR		Minimal activity	83
	34	3	18 weeks	Limited activity	84
	121	1 (n = 1 PR in S)	2.5–6 months	Minimal activity	85
Amrubicin	60	S: 52; Rs: 50	S: 12 months; Rs: 10 months	Significant activity	86
	35	S: 50; Rs/Rf: 60	S: 10 months; Rs/Rf: 7 months	Significant activity	87
	19	37		Active agent	88
	75	PR n = 13/39		Active agent	89
	60	38 versus 13		Amrubicin possibly superior to topotecan	90
Picoplatin	77		28 weeks	Compares favourably with other therapeutic options	65

OR: overall response; OS: overall survival; PR: partial response; S: sensitive (initially responded and then relapsed/progressed within 60–180 days); Rs: resistant (initially responded to first-line platinum-containing chemotherapy and then relapsed/progressed within 60–90 days); Rf: refractory (failed or progressed with first-line platinum-containing chemotherapy).